HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.

AbstractAIM:
To determine the effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
METHODS:
Seventeen Chinese patients with ventricular premature contractions (VPC> or =1000/d) were recruited. They were normal in routine laboratory testing and administered propafenone hydrochloride 450-600 mg per day in three divided doses. Twelve lead cardiogram and 24 h Holter monitoring were performed before and after 7 d treatment of propafenone. Steady-state peak and trough concentrations of propafenone were measured by HPLC method. CYP2D6*10 genotypes of patients were assayed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).
RESULTS:
Total inhibitory rate of VPC was 79.9 % in 17 patients with ventricular arrhythmia after propafenone treatment. PR interval prolongation was increased from 0.146 s+/-0.018 s to 0.161 s+/-0.022 s (P<0.05). CYP2D6 genotypes played an important role in plasma levels and effects of propafenone. In 450 mg/d group, patients with homozygous mutant of CYP2D6*10 not only had a Cmax of propafenone two times as high as those of wild-type genotype, but also showed a two fold higher inhibitory rate of VPC compared with those with homozygous CYP2D6*1 (P<0.05).
CONCLUSION:
CYP2D6*10 genotype is relevant to decreased activity of CYP2D6 enzyme in Chinese patients. Elevated plasma concentration is consistent with better efficacy of propafenone in patients with ventricular arrhythmia.
AuthorsWei-Min Cai, Jun Xu, Bing Chen, Fu-Min Zhang, Yuan-Zhu Huang, Yin-Di Zhang
JournalActa pharmacologica Sinica (Acta Pharmacol Sin) Vol. 23 Issue 11 Pg. 1040-4 (Nov 2002) ISSN: 1671-4083 [Print] United States
PMID12421483 (Publication Type: Journal Article)
Chemical References
  • Anti-Arrhythmia Agents
  • Propafenone
  • Cytochrome P-450 CYP2D6
Topics
  • Adult
  • Aged
  • Anti-Arrhythmia Agents (blood, pharmacology)
  • Arrhythmias, Cardiac (blood)
  • Cytochrome P-450 CYP2D6 (genetics, metabolism)
  • Female
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Propafenone (blood, pharmacology)
  • Ventricular Premature Complexes (blood, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: